Latest News and Press Releases
Want to stay updated on the latest news?
-
LIXTE (NASDAQ: LIXT) publishes new data showing that its lead compound LB-100 can mediate activation of oncogenic signaling, which is toxic to cancer cells
-
LIXTE Biotechnology (Nasdaq: LIXT) advancing its clinical strategy by focusing on high-need, high-value cancer indications that currently offer limited tre
-
LIXTE’s (Nasdaq: LIXT) lead compound, LB 100, was featured in Nature Reviews Cancer editorial titled “Too Much of a Good Thing”
-
2H 2025 is shaping up to be a defining year for LIXTE (Nasdaq: LIXT) and its lead compound LB-100
-
2025 is shaping up to be a defining year for LIXTE (Nasdaq: LIXT) and its lead compound LB-100
-
LIXTE’s (Nasdaq:LIXT) BoD approved a bold new treasury policy to diversify its corporate reserves into cryptocurrency, including $BTC & potentially others
-
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, April 07, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises GSK plc ("GSK" or the...
-
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, April 03, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises GSK plc ("GSK" or the...
-
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, March 31, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises GSK plc ("GSK" or the...
-
LOS ANGELES, March 27, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises GSK plc ("GSK" or the "Company") (NYSE: GSK) investors of a class action representing investors that bought securities...